Cargando…
PReS-FINAL-2326: No correlation between anti-drug antibodies and pharmacokinetics, efficacy or safety of Anakinra (Kineret(®)) in patients with severe CAPS
Autores principales: | Wikén, M, Gozzi, P, Andersson, G, Olivecrona, H, Aldén Raboisson, M, Kullenberg, T, Leinonen, M, Hallén, B |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4044047/ http://dx.doi.org/10.1186/1546-0096-11-S2-P316 |
Ejemplares similares
-
PW02-039 - Long-term anakinra treatment in CAPS: a metaanalys
por: Leinonen, M, et al.
Publicado: (2013) -
The IL-1 receptor antagonist anakinra (kineret®) stabilizes the NLRP3 mutation-specific risk for hearing loss in patients with severe cryopyrin-associated periodic syndromes (CAPS)
por: Leinonen, Mika, et al.
Publicado: (2014) -
Injection-site reactions upon Kineret (anakinra) administration: experiences and explanations
por: Kaiser, Christina, et al.
Publicado: (2011) -
Long-term safety profile of anakinra in patients with severe cryopyrin-associated periodic syndromes
por: Kullenberg, Torbjörn, et al.
Publicado: (2016) -
Anakinra (Kineret) in psoriasis and psoriatic arthritis: a single-center, open-label, pilot study
por: Gibbs, A, et al.
Publicado: (2005)